"Diketopiperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Piperazines with two keto oxygens.
| Descriptor ID |
D054659
|
| MeSH Number(s) |
D03.383.606.385
|
| Concept/Terms |
Diketopiperazines- Diketopiperazines
- Piperazinediones
- Diketopiperazine Compounds
- Diketopiperazine
|
Below are MeSH descriptors whose meaning is more general than "Diketopiperazines".
Below are MeSH descriptors whose meaning is more specific than "Diketopiperazines".
This graph shows the total number of publications written about "Diketopiperazines" by people in this website by year, and whether "Diketopiperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diketopiperazines" by people in Profiles.
-
Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. J Assoc Nurses AIDS Care. 2024 Sep-Oct 01; 35(5):437-449.
-
Improving Recruitment and Retention of Transgender Women in HIV Prevention Trials: Strategies to Make Trial Participation More Congruent with the Needs of Transgender Women. AIDS Res Hum Retroviruses. 2024 12; 40(12):680-689.
-
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024 Apr; 11(4):e211-e221.
-
The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch. Curr HIV/AIDS Rep. 2023 Oct; 20(5):271-285.
-
Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab Dispos. 2012 Oct; 40(10):1883-93.